<DOC>
	<DOCNO>NCT00277758</DOCNO>
	<brief_summary>This treatment study trial , assess safety tolerability daily dose IL-2 , monotherapy 12 week , follow IL2 combination PEG-IFN RBV 48 week treatment chronic Hepatitis C .</brief_summary>
	<brief_title>Safety Study Low Dose Interleukin 2 ( IL-2 ) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I</brief_title>
	<detailed_description>This single center study 12 week IL-2 lead immunotherapy follow 48 week IL2 immunotherapy combination Pegylated Interferon Alpha ( PEG-IFN-alpha ) /Ribavirin ( RBV ) antiviral therapy treatment individual infect Hepatitis C virus ( HCV ) genotype I . The study design determine whether immunotherapy immunotherapy low dose daily IL-2 safely add standard antiviral therapy 48 week PEG-IFN RBV . Because IL-2 target recently antigen- activated T cell , IL-2 therapy initiate 12 week PEG-IFN/RBV therapy , HCV antigen load high , activate expand HCV antigen-specific T cell prior initiation antiviral therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Men woman , age &gt; 18 year &lt; 65 year . Ability willingness sign inform consent . Hepatitis C antibody positive status confirm NYPH laboratory . Genotype 1 HCV confirm NYPH laboratory use DupliType assay perform Quest Diagnostics . Liver biopsy demonstrate chronic hepatitis without cirrhosis within 2 year enrollment . Prothrombin time &lt; 3 second longer control . Platelet count ≥75,000 mm3 Neutrophil count ≥ 1000/mm3 Hemoglobin ≥12 g/dL woman ≥13 g/dL men Subject must agree participate conception process ( define active attempt become pregnant impregnate , donate sperm , vitro fertilization etc . ) study drug 6 month follow permanent discontinuation study therapy . Women reproductive potential ( define study sexually mature woman postmenopausal least 24 consecutive month , undergone hysterectomy oophorectomy ) must negative serum urine pregnancy test sensitivity least 50 MIU/mL perform within 30 day prior enrollment within 24 hour initiate study therapy . All subject must participate conception process , participate sexual activity could lead pregnancy , male subject must take every precaution avoid risk pregnancy female partner , woman subjects/male partner must use two reliable method contraception simultaneously , receive study therapy 6 month follow permanent discontinuation study therapy . NOTE A : Reliable form contraception combination two follow method : 1 ) condom ( male female ) without spermicidal agent . 2 ) diaphragm cervical cap spermicide , 3 ) IUD , 4 ) hormonalbased contraception . NOTE B : An IUD adequate method contraception increase risk pelvic inflammatory disease . Previous IFNalpha , RBV IL2 therapy Any active viral hepatitis hepatitis C virus infection , define presence IgM antibody Hepatitis A Virus ( HAV ) within 30 day enrollment , Hepatitis B Virus Surface Antigen ( HBsAg ) positivity , positive plasma HBV DNA PCR methodology HB core antibody serologic marker HBV infection within 30 day entry . ALT AST &gt; 5x ULN , total bilirubin &gt; 1.5 x ULN Signs/symptoms advance liver disease . Uncontrolled infection , except hepatitis C HIV infection determine HIV ELISA &amp; Western blot assay , confirm plasma HIV assay ( PCR bDNA ) Cardiac condition control medication : Because risk anemia associate RBV use potential induce cardiac ischemia , subject positive cardiac stress test ineligible . Therefore , subject &gt; 40 year age ≥ 1 risk factor ASHD ( i.e. , hyperlipidemia , hypertension , smoke history , family history ) EKG preform . If EKG abnormal consistent ischemic heart disease , subject cardiac stress test R/O ASHD . CNS psychiatric illness uncontrolled medication . In particular , psychiatric illness , especially depression . Subjects psychiatric illness , previous suicide attempt hospitalization psychiatric Dx Will enrol discretion investigator . Concurrent therapy immunemodulating agent , e.g , . interleukin , interferon , therapeutic vaccine , corticosteroid , immunosuppressive agent ( azathioprine , 6mercaptopurine , CyclosporineA , FK506 , Rapamycin , antilymphocyte antibody ) . Pregnant nursing woman ( woman child bear age use effective contraception ) History malignancy receipt cancer therapy within 24 week . Any severe illness would make subject unsuitable study . Active asthma , asthma uncontrolled medication . Any immunologically mediate disease , include Crohn 's disease , ulcerative colitis , rheumatoid arthritis , lupus erythematosis , ITP , autoimmune hemolytic anemia , eczema , psoriasis . Untreated thyroid disease . Heroin cocaine use within 9 month enrollment . Inadequate venous access . NOTE : If screen TSH abnormal , obtain free thyroxin index . If free thyroxine index normal , subject may enter study . If free thyroxin index low , subject may treat thyroid hormone replacement medication enter study free thyroxin index correct . If free thyroxin index elevate indicate hyperthyroidism , subject enroll study . Patients preexistent antibody thyroid peroxidase thyroglobulin enrol . Allergy medication use study ( i.e. , IL2 , PEGIFN/RBV ) , component study product . Peg Intron : benzyl alcohol , NaCl , Naphosphate , EDTA , polysorbate 80 , mcresol , IL2 ; phosphate buffer , SDS , mannitol . RBV : cellulose , lactose , croscarmellose , magnesium stearate , Blue pharmaceutical ink : shellac , anhydrous ethyl alcohol , isopropyl alcohol , nbutyl alcohol , propylene glycol , ammonium hydroxide , Blue # 2 aluminum lake . Alcohol dependency , example , current alcohol use 1 drink/day time previous 6 month . One drink define 12 ounce beer , 5 ounce wine , 1¼ ounce hard liquor . Severe retinopathy due diabetes , hypertension , CMV , macular degeneration Acute therapy serious infection serious medical illness potentially life threaten require systemic therapy and/or hospitalization within 14 day study entry . Serum creatinine &gt; 2.0 mg/dL creatinine clearance &lt; 50 mL/min estimate CockcroftGault equation . This screen value must obtain within 30 day enrollment . History major organ transplantation exist graft . Subject judge investigator significant risk fail comply provision protocol cause harm self seriously interfere validity study result . Subjects biopsy proven liver disease HCV infection . Subjects hemoglobinopathies cause tendency toward hemolysis . Subjects chronic pulmonary disease functional limitation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Interleukin-2</keyword>
</DOC>